Research and development (including related party expenses of and 4,528 during the three and six months ended june30, 2025, respectively, and 2,551 and 3,212 during the three and six months ended june30, 2024, respectively)-Paragon Therapeutics
-
-
-
0
Total revenues
100
-
-
-
Research and development
71,577
77,631
86,261
86,626
General and administrative
-
-
24,322
20,216
Selling, general and administrative
54,975
38,679
-
-
Total operating expenses
126,552
116,310
110,583
106,842
Loss from operations
-126,268
-116,169
-40,013
-106,767
Interest income
8,490
7,872
5,521
-
Interest expense
8,307
3,462
560
514
Change in fair value of derivative liability
-1,190
7,530
-
-
Interest and other income
-
-
-
6,546
Other income (expense), net
156
-672
453
-
Total other income (expense), net
-851
11,268
5,414
6,032
Net loss
-127,119
-104,901
-34,599
-100,735
Unrealized gain (loss) on available-for-sale securities
-598
-1,008
294
-176
Foreign currency translation adjustment
3
3
-
-
Total other comprehensive income (loss)
-595
-1,005
294
-176
Comprehensive loss
-127,714
-105,906
-34,305
-100,911
Basic EPS
-1.05
-0.9
-0.34
-
Diluted EPS
-1.05
-0.9
-0.34
-
Basic Average Shares
107,884,104
102,211,657
81,784,499
-
Diluted Average Shares
107,884,104
102,211,657
81,784,499
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Time Plot
Show the time plot by selecting a row from the table.